172 related articles for article (PubMed ID: 33626423)
41. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
42. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
[TBL] [Abstract][Full Text] [Related]
43. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
44. Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.
Hiromoto S; Kawashiri T; Yamanaka N; Kobayashi D; Mine K; Inoue M; Uchida M; Shimazoe T
Sci Rep; 2021 Apr; 11(1):8964. PubMed ID: 33903667
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
46. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
47. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
Saif MW; Juneja V; Black G; Thronton J; Johnson MR; Diasio RB
Support Cancer Ther; 2007 Sep; 4(4):211-8. PubMed ID: 18632519
[TBL] [Abstract][Full Text] [Related]
48. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
49. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
Liang G; Ma W; Zhao Y; Liu E; Shan X; Ma W; Tang D; Li L; Niu X; Zhao W; Zhang Q
BMC Cancer; 2021 Apr; 21(1):362. PubMed ID: 33827689
[TBL] [Abstract][Full Text] [Related]
51. Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin.
Ma H; Chen M; Liu J; Li Y; Li J
An Bras Dermatol; 2015; 90(3 Suppl 1):209-11. PubMed ID: 26312719
[TBL] [Abstract][Full Text] [Related]
52. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
53. Palmar-plantar Erythrodysesthesia with Genital Involvement Secondary to Capecitabine Chemoradiotherapy: A Case Report.
Hu HP; Corkum MT; Perera F
Cureus; 2018 Dec; 10(12):e3704. PubMed ID: 30788193
[TBL] [Abstract][Full Text] [Related]
54. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
55. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S
J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477
[TBL] [Abstract][Full Text] [Related]
56. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
Molpus KL; Anderson LB; Craig CL; Puleo JG
Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
[TBL] [Abstract][Full Text] [Related]
58. Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients.
Kayikci EE; Can G; Sen F; Saip P
Florence Nightingale J Nurs; 2020 Oct; 28(3):299-311. PubMed ID: 34263209
[TBL] [Abstract][Full Text] [Related]
59. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Filip S; Kubeček O; Špaček J; Lánská M; Bláha M
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33008072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
